Critical uncertainties persist concerning ideal candidate identification, therapeutic sequence, combination strategies with other emerging MASH therapies, long-term durability of benefits, and cost-effectiveness
n=338) demonstrated dose-dependent weight loss over 48 weeks: The 24.2% weight loss at the 12 mg dose was the largest mean weight loss reported for any anti-obesity medication at the time of publication
GLP-1RAs are associated with greatest weight loss, and have shown their ability to decrease the risk of cardiovascular (CV) events in individuals with T2D at risk of CV disease
HEDISON: Innovations in the Field of Cosmetics DR
No more impulse eating
You may experience decreased energy, fatigue, brain fog, and joint and head pain, among other issues